Seanad Éireann Debate on NCPE Cost-Benefit Analysis (oireachtas.ie)

• Critical examination of NCPE methodology and transparency
• Impact on HSE drug reimbursement decisions
• Concerns over patient access to innovative therapies

"A Seanad Éireann debate on February 5, 2026, critically examined the National Centre for Pharmacoeconomics (NCPE) cost-benefit analysis for drugs, which directly influences reimbursement policy and patient access in Ireland. Senators raised concerns about transparency and methodology, emphasizing the need for a balanced approach that does not unduly delay patient access to innovative treatments."